 |
Roche Enters $1.1B Deal With Aileron To Produce New Drugs
August 24 2010
"Roche Holding AG (ROG.VX) Tuesday entered into a partnership deal with U.S.-based biopharmaceutical firm Aileron Therapeutics to produce...."
|
|
|
Roche Backs New Method for Drug Delivery to Cells
August 24 2010
"Roche agreed to pay up to $1.1 billion to Aileron Therapeutics, which is developing a new type of drug technology called stapled peptides."
|
|
|
Stapled Peptides on the cover of the August issue of Nature Chemical Biology
August 1 2010
"Discovery of a stapled peptide inhibitor of Mcl-1. Stewart et al. screened a library of stapled peptides based on the BH3 domains of BCL-2 family...."
|
|
 |
HeartWare Announces Board Succession
June 24 2010
"HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that C. Raymond Larkin, Jr., who joined the Board in...."
|
|
|
HeartWare Receives Conditional FDA Approval to Commence Pivotal Destination Therapy Clinical Trial in the U.S.
June 14 2010
"HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted...."
|
|
|
HeartWare Data From First 100 Patients in International Clinical and Commercial Experience Shows 90% Survival at 180 Days
April 23 2010
"HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that data from its international clinical trial and...."
|
|
|
HeartWare Receives FDA Approval of Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
April 7 2010
"HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved...."
|
|
|
HeartWare Announces Early Conclusion of Enrollment for U.S. Bridge-to-Transplant Clinical Trial
February 22 2010
"HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced the conclusion of...."
|
|
|
HeartWare International, Inc. Announces Completion of Public Offering of Common Stock
February 2 2010
"HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN) ("HeartWare") announced today the completion of a public offering of 1,767,900 shares of its common stock...."
|
|
|
HeartWare International, Inc. Announces Commencement of Public Offering of Common Stock
January 26 2010
"HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN) ("HeartWare") announced today a public offering of 1,500,000 shares of its common stock."
|
|
 |
Celgene to Acquire Gloucester Pharmaceuticals
December 7 2009
"Celgene Corporation (NASDAQ:CELG) and Gloucester Pharmaceuticals Inc., a privately held pharmaceutical company, announced a definitive merger agreement under which Celgene Corporation will acquire Gloucester Pharmaceuticals...."
|
|
 |
Tokai eyes novel weapon to battle prostate cancer
November 27 2009
"Tokai Pharmaceuticals has begun a clinical trial for a new prostate cancer drug candidate after quietly raising cash over the...."
|
|
|
Aileron Therapeutics Collaborators Publish In Vivo Research in Nature Showing Stapled Peptides Achieve the First Direct Inhibition of the Notch1 Transcription Factor Oncogene
November 11 2009
"Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides...."
Link to Abstract
|
|
|
Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program for TOK-001; First Ever Multi-Target Investigational Drug for Prostate Cancer
November 10 2009
"Tokai Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the...."
|
|
|
FDA Approves Gloucester Pharmaceuticals' ISTODAX® for Patients with Cutaneous T-cell Lymphoma
November 5 2009
"Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin)...."
|
|
|
FDA Advisory Committee Recommends Gloucester Pharmaceuticals’ Romidepsin for Approval for Cutaneous T-cell Lymphoma
September 2 2009
"Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the...."
|
|
|
Gloucester raises $29 million
August 25 2009
"Gloucester Pharmaceuticals Inc. (Cambridge, Mass.) raised $29 million in a series D round led by new investor Novo A/S. ...."
|
|
|
HeartWare International Surpasses 50 Implants In The US
August 21 2009
"HeartWare International, Inc. (NASDAQ: HTWR) (ASX: HIN) today announced that HeartWare has surpassed 50 implants in the...."
|
|
|
HeartWare International, Inc. Closes US$60 Million Financing
August 17 2009
"HeartWare International, Inc. (NASDAQ: HTWR) (ASX: HIN) announced today the completion of its offering of approximately...."
|
|
|
Drug giants pump $40m into Aileron
June 9 2009
"Four global pharmaceutical companies have joined in a consortium to provide $40 million in financing to Aileron Therapeutics...."
|
|
|
Aileron Therapeutics Closes $40M Financing To Advance Stapled Peptide Platform
June 8 2009
"Company Developing Novel Class of Stapled Peptide Drugs as Technology Platform for Historically Undruggable Targets...."
|
|
|
"Emerging Drug Developer" Tokai Pharmaceuticals
June 1 2009
"Seth Harrison knows a thing or two about jump-starting a biotech company without breaking the bank...."
|
|
|
Aileron Advances First Stapled Peptide Drug Candidate
that Targets Newly-Discovered BAX Activation Mechanism
October 22, 2008
"Aileron Therapeutics announced today that one
of its proprietary Stapled Peptide compounds, referred to as “BIM-SAHB” in an article published today in Nature..."
|
